Skip to main content

Table 2 Summary of major clinical events registered after hospital discharge in both patient groups over the 5-year follow-up

From: Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial

 

EPO

(n = 68)

Placebo

(n = 70)

 

Death; n(%)

8 (11.8)

6 (8.6)

p = 0.53

MI; n(%)

4 (5.9)

2 (2.9)

p = 0.38

Death or MI; n(%)

10 (14.7)

7 (10.0)

p = 0.40

Stroke; n(%)

1 (1.5)

0 (0)

p = 0.31

Death or MI or Stroke; n(%)

10 (14.7)

7 (10.0)

p = 0.40

Coronary bypass surgery; n(%)

1 (1.5)

0 (0)

p = 0.31

Target lession revascularization; n(%)

15 (22.1)

9 (12.9)

p = 0.15

MACE; n(%)

17 (25.0)

12 (17.1)

p = 0.26